Tianyu Pharmaceutical, Co., Ltd was established in 1993. It is engaged in the research, development and manufacturing of APIs and advanced intermediates with a registered capitalization of RMB120 million. The company comprises 6 wholly-owned subsidiaries with a total employee population in excess of 2600 and occupying an area of over 470,000 ㎡. Tianyu is recognized as a model high-tech enterprise in Chinas Torch Program.

Tianyu is specializing in pharmaceutical intermediates and APIs of cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant and anti-asthmatic series. The products are well sold to domestic and overseas markets, winning customer’s recognition and praise.

Quality is an intrinsic value of Tianyu. The company has passed USFDA and the EMEA GMP on-site inspections as well as by authorities from China, Japan, Korea and other countries. 8 APIs have received EUGMP Certificatesor FDA EIR. 4 APIs have GMP certifications by SFDA. Over 50% of Tianyu’s products are supplied to well-known national and international pharmaceutical companies. The GMP system, excellent production equipment and methodology, state-of-the-art instruments, and network-based data management all serve to insure the quality and reliability of our products.

Innovation is the engine of Tianyu’s development. To date, Tianyu has accumulated 12 national or international patents and filed for patents in two NCE APIs and is cited as a model innovation and patents enterprise that provides exemplary products and services to the world’s leading drug makers.

Adhering to the concept of excellence, delicacy and strength, Tianyu takes social responsibility as its duty, and regards continuous

improvement as its principle, to form a community of interests between customers, employees, partners and Tianyu, to provide customer with high-quality products and service, and to contribute to health welfare of mankind.